期刊文献+

miRNA deregulation in multiple myeloma 被引量:5

miRNA deregulation in multiple myeloma
原文传递
导出
摘要 Multiple myeloma (MM) is an incurable plasma cell malignancy and is the second most common hematological cancer. It is characterized by complex, recurrent genetic and epigenetic abnormalities. Recent publications have linked miRNAs, a novel class of gene regulators to cancer including MM. miRNAs are about 20 nucleotide, single strand, non-coding RNAs that repress gene expression by mRNA degradation or translational repression. Aberrant miRNA expression profiles have been described in MM, and their functional roles in MM pathogenesis are being increasingly recognized. This review summarizes the current literature on the role of miRNAs in MM and offers perspectives on future research and utilization of miRNAs in MM management. Multiple myeloma (MM) is an incurable plasma cell malignancy and is the second most common hematological cancer. It is characterized by complex, recurrent genetic and epigenetic abnormalities. Recent publications have linked miRNAs, a novel class of gene regulators to cancer including MM. miRNAs are about 20 nucleotide, single strand, non-coding RNAs that repress gene expression by mRNA degradation or translational repression. Aberrant miRNA expression profiles have been described in MM, and their functional roles in MM pathogenesis are being increasingly recognized. This review summarizes the current literature on the role of miRNAs in MM and offers perspectives on future research and utilization of miRNAs in MM management.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2011年第19期3164-3169,共6页 中华医学杂志(英文版)
关键词 MIRNA multiple myeloma PATHOGENESIS GENETICS chromosome 13 miRNA multiple myeloma pathogenesis genetics chromosome 13
  • 相关文献

参考文献58

  • 1Chng WJ,Lau LG,Yusof N,Mow BM.Targeted therapy in multiple myeloma.Cancer Control 2005; 12:91-104.
  • 2Raab MS,Podar K,Breitkreutz I,Richardson PG,Anderson KC.Multiple myeloma.Lancet 2009; 374:324-339.
  • 3Kumar S.Multiple myeloma:current issues and controversies.Cancer Treat Rev 2010; 36:3-11.
  • 4Kyle RA,Themeau TM,Rajkumar SV,Offord JR,Larson DR,Plevak MF,et al.A long-term study of prognosis in monoclonal gammopathy of undetermined significance.N Engl J Med 2002; 346:564-569.
  • 5Kyle RA,Therneau TM,Rajkumar SV,Larson DR,Plevak MF,Offord JR,et al.Prevalence of monoclonal gammopathy of undetermined significance.N Engl J Med 2006; 354:1362-1369.
  • 6Kuehl WM,Bergsagel PL.Multiple myeloma:evolving genetic events and host interactions.Nat Rev Cancer 2002; 2:175-187.
  • 7Chng WJ,Glebov O,Bergsagel RL,Kuehl WM.Genetic events in the pathogenesis of multiple myeloma.Best Pract Res Clin Haematol 2007; 20:571-596.
  • 8Bi CL,Chng W.Molecular genetics of multiple myeloma.Chichester: John Wiley & Sons, Ltd.; 2010: DOI:10.1002/9780470015902.a0022446.
  • 9Kyle RA,Rajkumar SV.Multiple myeloma.Blood 2008; 111:2962-2972.
  • 10Bartel DP.MicroRNAs:genomics,biogenesis,mechanism,and function.Cell 2004; 116:281-297.

同被引文献18

引证文献5

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部